Two promising therapeutic strategies in oncology are chimeric antigen receptor-T cell (CAR-T) therapies and antibody-drug conjugates (ADCs). To be effective and safe, these immunotherapies require surface antigens to be sufficiently expressed in tumors and less or not expressed in normal tissues. To identify new targets for ADCs and CAR-T specifically targeting breast cancer (BC) molecular and pathology-based subtypes, we propose a novel in silico strategy based on multiple publicly available datasets and provide a comprehensive explanation of the workflow for a further implementation.
Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer / Schettini, F; Barbao, P; Brasó-Maristany, F; Galván, P; Martínez, D; Paré, L; De Placido, S; Prat, A; Guedan, S. - In: ESMO OPEN. - ISSN 2059-7029. - 6:3(2021), p. 100102. [10.1016/j.esmoop.2021.100102]
Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer
Schettini, F;De Placido, S;
2021
Abstract
Two promising therapeutic strategies in oncology are chimeric antigen receptor-T cell (CAR-T) therapies and antibody-drug conjugates (ADCs). To be effective and safe, these immunotherapies require surface antigens to be sufficiently expressed in tumors and less or not expressed in normal tissues. To identify new targets for ADCs and CAR-T specifically targeting breast cancer (BC) molecular and pathology-based subtypes, we propose a novel in silico strategy based on multiple publicly available datasets and provide a comprehensive explanation of the workflow for a further implementation.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
